申请人:Centocor Ortho Biotech Products L.P.
公开号:EP2166016A1
公开(公告)日:2010-03-24
Compounds of formula I :
R1 is hydrogen, C1-C4alkyl, OH, C1-C4alkoxy;
R2 is phenyl, optionally substituted with 1, 2 or 3 substituents each independently selected from halo, C1-C6alkyl, and C1-C6alkoxy, or R2 is naphtalenyl;
R3 is hydrogen, C1-C6alkyl, benzyl;
R4 is hydrogen, C1-C6alkyl, benzyl; or
R3 and R4 together with the carbon atom to which they are attached form C3-C7cycloalkyl;
R5 is C1-C6alkyl, benzyl, or phenyl, optionally substituted with 1, 2 or 3 substituents each independently selected from hydroxy, C1-C6alkoxy, amino, mono- and diC1-C6alkylamino;
or a pharmaceutically acceptable salt or solvate thereof;
useful in the prophylaxis or treatment of HCV infections.
公式I的化合物:R1是氢、C1-C4烷基、羟基、C1-C4烷氧基;R2是苯基,可选地取代有1、2或3个取代基,每个取代基独立选择自卤素、C1-C6烷基和C1-C6烷氧基,或者R2是萘基;R3是氢、C1-C6烷基、苄基;R4是氢、C1-C6烷基、苄基;或者R3和R4与它们连接的碳原子一起形成C3-C7环烷基;R5是C1-C6烷基、苄基或苯基,可选地取代有1、2或3个取代基,每个取代基独立选择自羟基、C1-C6烷氧基、氨基、单烷基和双烷基氨基;或其药学上可接受的盐或溶剂;用于预防或治疗丙型肝炎感染。